BioAtla reports Q4 net loss $26.9M vs. $27.6M last year

Reports net cash used in operating activities for the full year ended December 31 was $104M compared to net cash used in operating activities of $90.4M for the same period in 2022. Cash used for the quarter ended December 31 was $29.8M…Cash and cash equivalents as of December 31 were $111.5M compared to $215.5M as of December 31, 2022. “We expect our current cash and cash equivalents will be sufficient to fund operations into the second half of 2025…”BioAtla continued to make considerable progress in 2023 across both of our CAB-ADC clinical trials targeting multiple tumor types, as well as advancing our CAB-CTLA-4 clinical asset, BA3071, with recent clearance of the DLT observation period at the 10 mg/kg dosing cohort,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “We are excited to have several upcoming important milestones in the second quarter of this year including: initial data readouts from our Phase 2 BA3071 study; Phase 2 data for CAB-ROR2-ADC, BA3021, in both melanoma and head and neck cancer; and evaluation of clinical benefit in AXL-agnostic patients in our CAB-AXL-ADC, BA3011, Phase 2 NSCLC extension study. As we finalize these data sets in preparation for potentially registrational trials across our lead programs, we are engaging with potential pharmaceutical partners that are capable of accelerating development and maximizing the value of selected assets.”